Suven Life Sciences Ltd vs Syngene International Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Suven Life Sciences Ltd is ₹ 258.1 as of 30 Oct 15:30 . The P/E Ratio of Suven Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Suven Life Sciences Ltd changed from ₹ 896.07 crore on March 2021 to ₹ 3503 crore on March 2026 . This represents a CAGR of 25.51% over 6 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Suven Life Sciences Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 11.09 crore. This represent the decline of -100% The revenue of Syngene International Ltd for the Sep '26 is ₹ 860.7 crore as compare to the Jun '26 revenue of ₹ 761.3 crore. This represent the growth of 13.06% The ebitda of Suven Life Sciences Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ -124 crore. This represent the decline of -100% The ebitda of Syngene International Ltd for the Sep '26 is ₹ 168.7 crore as compare to the Jun '26 ebitda of ₹ 102.6 crore. This represent the growth of 64.42% The net profit of Suven Life Sciences Ltd changed from ₹ -28.04 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of -100.00% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ 32.2 crore over 10 quarters. This represents a CAGR of -28.96% The Dividend Payout of Suven Life Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .

About Suven Life Sciences Ltd

Suven Life Sciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated in March, 1989.
The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003.
Promoted by Venkateswarlu Jasti, Company began its operations in 1989 as specialty chemicals provider. The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies. The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors.

About Syngene International Ltd

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers. Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.

FAQs for the comparison of Suven Life Sciences Ltd and Syngene International Ltd

Which company has a larger market capitalization, Suven Life Sciences Ltd or Syngene International Ltd?

Market cap of Suven Life Sciences Ltd is 7,292 Cr while Market cap of Syngene International Ltd is 16,251 Cr

What are the key factors driving the stock performance of Suven Life Sciences Ltd and Syngene International Ltd?

The stock performance of Suven Life Sciences Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Suven Life Sciences Ltd and Syngene International Ltd?

As of October 31, 2026, the Suven Life Sciences Ltd stock price is INR ₹258.1. On the other hand, Syngene International Ltd stock price is INR ₹402.6.

How do dividend payouts of Suven Life Sciences Ltd and Syngene International Ltd compare?

To compare the dividend payouts of Suven Life Sciences Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.